The year 2020 has gotten off to a flying start—probably a direct consequence of 2019 finishing with a flurry. One of the first eye-catching bits of news was the request by several states for the Supreme Court to intervene now, not later, in the case that threatens the fundamental basis on which the biosimilar pathway … Continue reading Will the Supreme Court Fast Forward Health Insurance Reform in 2020?
Tag: Supreme Court
What Happens When Switching Among Biosimilars?
A health plan would not likely cover both infliximab biosimilars and the reference product. At some point, the plan will seek a contract that leverages marketshare.
US Supreme Court Strikes Down 180-Day Waiting Period
In a unanimous decision, the Supreme Court rejected Amgen’s oral arguments—a biosimilar manufacturer can meet the 180-day notification period requirement by notifying the originator’s manufacturer before receiving approval. In other words, biosimilar launches can occur immediately after approval by the Food and Drug Administration (FDA).
No Clear Winner on Supreme Court’s Biosimilar Hearing Day
Despite the fact that the arguments at Wednesday's Supreme Court wrestling match on the patent dance and 180-day notification issue went into overtime, there was no clear winner discernable in Amgen v. Sandoz.
Supreme Court to Hear Sandoz v. Amgen Arguments on the 180-Day Notification Period
It seems that the Supreme Court will in fact hear Novartis’ case in an attempt to overturn the 180-day notification period, as part of the “patent dance.” Its biosimilar-making subsidiary (Sandoz) will finally get its day in the nation’s top court in April, with a decision expected sometime in July.